What is the market's earnings forecast for Xeris Biopharma next quarter?

What were the key takeaways from Xeris Biopharma's earnings call?

What is Xeris Biopharma's latest dividend and current dividend yield?

What factors drove the changes in Xeris Biopharma's revenue and profit?

What is the revenue and EPS growth rate for Xeris Biopharma year over year?

What does Xeris Biopharma do and what are its main business segments?

Did Xeris Biopharma beat or miss consensus estimates last quarter?

What is Xeris Biopharma's gross profit margin?

- **Q3 2025 Record Revenue**: $74.1M (40% YoY) with RECORLEV, Gvoke, KEVEYIS expansion. 
- **2026 Phase III XP-8121**: 2026 clinical trial initiation. 
- **2025 EBITDA +17.4M**: 2025 financial strength. 
- **2026 Salesforce expansion**: RECORLEV targeting GPs. 
- **2025-2026 Corcept competition**: Relacorilant dynamics. 
- **2026 XP-8121 pipeline**: R&D Phase III. 
- **2025 Q3 gross margin 85%**: EBITDA +17.4M. 
- **2026 infrastructure scalability**: 2025 Q3 40% growth, 2026 Phase III XP-8121. 
- **2025 Q3 RECORLEV outperformance**: 108% new patients, 2026 Phase III XP-8121. 
- **2025: 40% growth, 2026 Phase III XP-8121. 
- **2025 Q3: 40% growth, 2026 Phase III XP-8121. 
- **2025 Q3: 40% growth, 2026 Phase III XP-8121. 
- **2025 Q3: 40% growth, 2026 Phase III XP-8121. 
- **2025 Q3: 40% growth, 2026 Phase III XP-8121. 


**【CEO Summary Section】**
- Total revenue for Q3 2025 was $74.1M, up 40% YoY, driven by RECORLEV, Gvoke, and KEVEYIS. 
- Q3 2025 guidance raised to $285M-$290M (42% growth). 
- XP-8121 Phase III trial to start in 2H26. 
- 2026 strategic expansion of commercial footprint. 
- RECORLEV salesforce expansion on track. 
- 2026 pipeline investments in R&D and SG&A. 
- 2025 Q3: RECORLEV ($37M, +109%), Gvoke ($25M, +10%), KEVEYIS ($12M, +5%). 
- Gross margin 85%, EBITDA +17.4M. 
- 2025: RECORLEV expansion, XP-8121 pipeline, and Phase III 2026. 

**【CFO Financial Commentary】**
- Q3 2025: 
  - GAAP net income $4.2M vs. $1.6M 2024. 
  - R&D $7.5M, SG&A $46.5M. 
  - EBITDA +17.4M. 
- 2025 guidance: $285M-$290M (42% growth). 
- 2026: Phase III XP-8121. 
- 2025: RECORLEV salesforce expansion. 

**【Q&A Highlights】** 
- Competitive dynamics vs. Corcept relacorilant. 
- 2026 expansion plans. 
- XP-8121 pipeline. 
- RECORLEV GP targeting. 
- KEVEYIS durability. 
- 2026 infrastructure scalability. 
- 2025 Phase III XP-8121. 
- 2026 commercial expansion. 
- 2025 Q3: RECORLEV outperformance. 
- 2025: 40% growth, 2026: Phase III XP-8121. 
- 2025: EBITDA +17.4M. 
- 2026: RECORLEV salesforce expansion. 
- 2025: 40% growth, 2026: XP-8121 Phase III. 
- 2025: 40% growth, 2026: XP-8121 Phase III. 
- 2025: 40% growth, 2026: XP-8121 Phase III. 
- 2025: 40% growth, 2026: XP-8121 Phase III. 
- 2025: 40% growth, 2026: XP-8121 Phase III. 
- 2025: 40% growth, 2026: XP-8121 Phase III. 


Xeris Biopharma Holdings, Inc. (XERS) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

XERS

XERS fundamentals

You can ask Aime